PSMA-targeted radiotracer pinpoints metastatic prostate cancer across anatomic regions
A phase III clinical trial has validated the effectiveness of the prostate-specific membrane antigen (PSMA)-targeted radiotracer 18F-DCFPyL in detecting and localizing recurrent prostate cancer. Approved by the U.S. Food ...
Jun 15, 2021
0
3